AMGEN INC — Director's Dealing 2024

May 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-05-07

Reporting Person: Bradway Robert A (Director, Chairman, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-07	Common Stock	A	11988	—	Acquired	669269	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-07	Nqso (Right to Buy)	$300.30	A	77877	Acquired	2034-05-07	Common Stock (77877)	Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,516 RSUs which will vest on 4/30/2025; 9,234 RSUs which will vest in installments of 4,548 on 5/2/2025, and 4,686 on 5/2/2026; 13,486 RSUs which will vest in two installments of 4,450 each on 5/2/2025 and 5/2/2026, and one installment of 4,586 on 5/2/2027; and 11,988 RSUs which will vest in two installments of 3,956 on 5/7/2026 and on 5/7/2027, and one installment of 4,076 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 1,555 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F3: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.